Laura C. Michaelis

Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia

Geoffrey L. Uy, Ibrahim Aldoss, Matthew C. Foster et al. · Blood · 2020 · 307 citations · Full text

Oral cedazuridine/decitabine for MDS and CMML: a phase 2 pharmacokinetic/pharmacodynamic randomized crossover study

Guillermo Garcia‐Manero, Elizabeth A. Griffiths, David P. Steensma et al. · Blood · 2020 · 205 citations · Full text

American Society of Hematology 2020 guidelines for treating newly diagnosed acute myeloid leukemia in older adults

Mikkael A. Sekeres, Gordon Guyatt, Gregory A. Abel et al. · Blood Advances · 2020 · 176 citations · Full text

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors

Mohamed Shanavas, Uday Popat, Laura C. Michaelis et al. · Biology of Blood and Marrow Transplantation · 2015 · 142 citations · Full text

Antifibrotic Therapy, Immunology, Pathology +16

An oral fixed-dose combination of decitabine and cedazuridine in myelodysplastic syndromes: a multicentre, open-label, dose-escalation, phase 1 study

Michael R. Savona, Olatoyosi Odenike, Philip C. Amrein et al. · The Lancet Haematology · 2019 · 119 citations

Hematological Malignancy, Oral Fixed-dose Combination, Pharmacology +6